{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:20:25Z","timestamp":1744777225361,"version":"3.40.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40290-021-00400-0","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T06:03:01Z","timestamp":1630994581000},"page":"281-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Why Does the Precautionary Principle Suffice for Blood Regulation?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-4216","authenticated-orcid":false,"given":"Alexandra","family":"Seifner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony W.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"400_CR1","doi-asserted-by":"crossref","unstructured":"Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. Hematol Am Soc Hematol Educ Progr. 2003;2013:638\u201344.","DOI":"10.1182\/asheducation-2013.1.638"},{"issue":"4","key":"400_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Investig. 2020;130(4):1545\u20138.","journal-title":"J Clin Investig"},{"issue":"6506","key":"400_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014\u20138.","journal-title":"Science"},{"issue":"11","key":"400_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","volume":"26","author":"STH Liu","year":"2020","unstructured":"Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26(11):1708\u201313.","journal-title":"Nat Med"},{"issue":"4","key":"400_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","volume":"20","author":"L Chen","year":"2020","unstructured":"Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398\u2013400.","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"400_CR6","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"400_CR7","unstructured":"FDA Emergency Use Authorization. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization. Accessed 5 Aug 2021."},{"key":"400_CR8","unstructured":"Drugs@FDA\u2013Remdesivir. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Search term: Remdesivir. Accessed 5 Aug 2021."},{"issue":"13","key":"400_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2020.16253","volume":"324","author":"K Thomson","year":"2020","unstructured":"Thomson K, Nachlis H. Emergency use authorizations during the COVID-19 pandemic: lessons from hydroxychloroquine for vaccine authorization and approval. JAMA. 2020;324(13):1282\u20133.","journal-title":"JAMA"},{"key":"400_CR10","unstructured":"Keeping blood transfusion safe: FDA\u2019s multi-layered protections for donated blood. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/keeping-blood-transfusions-safe-fdas-multi-layered-protections-donated-blood. Accessed 5 Aug 2021."},{"key":"400_CR11","unstructured":"EUR-Lex. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/ALL\/?uri=CELEX%3A32002L0098. Accessed 5 Aug 2021."},{"key":"400_CR12","unstructured":"EUR-Lex. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32004L0033. Accessed 5 Aug 2021."},{"key":"400_CR13","unstructured":"EUR-Lex. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/ALL\/?uri=celex:32005L0061. Accessed 5 Aug 2021."},{"key":"400_CR14","unstructured":"EUR-Lex. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/ALL\/?uri=CELEX%3A32005L0062. Accessed 5 Aug 2021."},{"key":"400_CR15","unstructured":"EUR-Lex. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32016L1214. Accessed 5 Aug 2021."},{"key":"400_CR16","unstructured":"WHO Blood Products. https:\/\/www.who.int\/health-topics\/blood-products#tab=tab_1. Accessed 5 Aug 2021."},{"key":"400_CR17","unstructured":"Tainted Blood Timeline. https:\/\/www.taintedblood.info\/timeline\/. Accessed 5 Aug 2021."},{"key":"400_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/trf.12569","volume":"54","author":"JE Menitove","year":"2014","unstructured":"Menitove JE, Bennett JL, Tomasulo P, Katz LM. How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making. Transfusion. 2014;54:753\u20137.","journal-title":"Transfusion"},{"issue":"11","key":"400_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1503\/cmaj.071333","volume":"177","author":"K Wilson","year":"2007","unstructured":"Wilson K. The Krever Commission\u201310 years later. CMAJ. 2007;177(11):1387\u20139.","journal-title":"CMAJ"},{"key":"400_CR20","unstructured":"Infected Blood Inquiry. https:\/\/www.infectedbloodinquiry.org.uk\/. Accessed 5 Aug 2021."},{"issue":"2","key":"400_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tmrv.2008.12.007","volume":"23","author":"EC Vamvakas","year":"2009","unstructured":"Vamvakas EC. Scientific background on the risk engendered by reducing the lifetime blood donation deferral period for men who have sex with men. Transfus Med Rev. 2009;23(2):85\u2013102.","journal-title":"Transfus Med Rev"},{"issue":"2","key":"400_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/trf.12809","volume":"55","author":"RW Lieshout-Krikke","year":"2015","unstructured":"Lieshout-Krikke RW, Zaaijer HL, van de Laar TJ. Predonation screening of candidate donors and prevention of window period donations. Transfusion. 2015;55(2):373\u20138.","journal-title":"Transfusion"},{"key":"400_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001623","volume":"11","author":"K Wilson","year":"2014","unstructured":"Wilson K, Atkinson K, Keelan J. The use of preliminary scientific evidence in public health: a case study of XMRV. PLoS Med. 2014;11:1\u20134.","journal-title":"PLoS Med"},{"issue":"2","key":"400_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/trf.14164","volume":"57","author":"KD Ellingson","year":"2017","unstructured":"Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Henry RA, Berger JJ, Kuehnert MJ, Basavaraju SV. Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States. Transfusion. 2017;57(2):1625\u201333.","journal-title":"Transfusion"},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1046\/j.1423-0410.2002.00198.x","volume":"83","author":"M van Hulst","year":"2002","unstructured":"van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang. 2002;83:146\u201355.","journal-title":"Vox Sang"},{"issue":"7","key":"400_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1046\/j.1537-2995.1995.35795357874.x","volume":"35","author":"F Le Pont","year":"1995","unstructured":"Le Pont F, Costagliola D, Rouzioux C, Valleron AJ. How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests? Transfusion. 1995;35(7):542\u20137.","journal-title":"Transfusion"},{"issue":"7","key":"400_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1537-2995.1995.35795357872.x","volume":"35","author":"MP Busch","year":"1995","unstructured":"Busch MP, Alter HJ. Will human immunodeficiency virus p24 antigen screening increase the safety of the blood supply and if so, at what cost? Transfusion. 1995;35(7):536\u20139.","journal-title":"Transfusion"},{"key":"400_CR28","unstructured":"America\u2019s Blood Centers: ABC calls on the FDA to cease testing for Zika virus. https:\/\/americasblood.org\/news\/abc-calls-on-the-fda-to-cease-testing-for-zika-virus\/. Accessed 5 Aug 2021."},{"issue":"3","key":"400_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.7326\/M18-2238","volume":"170","author":"WA Russell","year":"2019","unstructured":"Russell WA, Stramer SL, Busch MP, Custer B. Screening the blood supply for Zika virus in the 50 U.S. States and Puerto Rico: a cost-effectiveness analysis. Ann Intern Med. 2019;170(3):164\u201374.","journal-title":"Ann Intern Med"},{"key":"400_CR30","unstructured":"Cooper K. Presentation\u2014TACO. https:\/\/www.transfusionguidelines.org\/document-library\/documents\/taco-karen-cooper-presentation-apr-17-pdf. Accessed 5 Aug 2021."},{"issue":"2","key":"400_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/blood-2010-05-286146","volume":"117","author":"UJH Sachs","year":"2011","unstructured":"Sachs UJH, Wasel W, Bayat B, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood. 2011;117(2):669\u201377.","journal-title":"Blood"},{"issue":"5","key":"400_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.transci.2019.07.011","volume":"58","author":"APJ Vlaar","year":"2019","unstructured":"Vlaar APJ, Kleinman S. An update of the transfusion-related acute lung injury (TRALI) definition. Transfus Apher Sci. 2019;58(5):632\u20133.","journal-title":"Transfus Apher Sci"},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/asheducation-2018.1.585","volume":"1","author":"N Roubinian","year":"2018","unstructured":"Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematology. 2018;1:585\u201394.","journal-title":"Hematology"},{"key":"400_CR34","doi-asserted-by":"crossref","unstructured":"Wang KY, Shah P, Pierce M. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI. BMJ case reports CP; 2021.","DOI":"10.1136\/bcr-2020-239762"},{"issue":"5","key":"400_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bjh.15082","volume":"180","author":"NH Saadah","year":"2018","unstructured":"Saadah NH, van der Bom JG, Wiersum-Osselton JC, Richardson C, Middelburg RA, Politis C, Renaudier P, Robillard P, Schipperus MR. Comparing transfusion reaction risks for various plasma products\u2014an analysis of 7 years of ISTARE haemovigilance data. Br J Haematol. 2018;180(5):727\u201334.","journal-title":"Br J Haematol"},{"issue":"2","key":"400_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tracli.2009.03.001","volume":"16","author":"JC Faber","year":"2009","unstructured":"Faber JC. Revue des principaux syst\u00e8mes d\u2019h\u00e9movigilance dans le monde [Review of the main haemovigilance systems in the world]. Transfus Clin Biol. 2009;16(2):86\u201392.","journal-title":"Transfus Clin Biol"},{"issue":"4","key":"400_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/tme.12582","volume":"29","author":"EM Wood","year":"2019","unstructured":"Wood EM, Ang AL, Bisht A, Bolton-Maggs PH, Bokhorst AG, Flesland O, Land K, Wiersum-Osselton JC, Schipperus MR, Tiberghien P, Whitaker BI. International haemovigilance: what have we learned and what do we need to do next? Transfus Med. 2019;29(4):221\u201330.","journal-title":"Transfus Med"},{"key":"400_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/bja\/aeh290","volume":"95","author":"C Madjdpour","year":"2005","unstructured":"Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: Efficacy, risks, alternatives and indications. Br J Anaesth. 2005;95:33\u201342.","journal-title":"Br J Anaesth"},{"issue":"1","key":"400_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/voxs.12018","volume":"8","author":"EL Murphy","year":"2013","unstructured":"Murphy EL. Health outcomes in recipients of blood transfusion\u2014observational studies versus randomized clinical trials. ISBT Sci Ser. 2013;8(1):172\u20136.","journal-title":"ISBT Sci Ser"},{"issue":"5","key":"400_CR40","doi-asserted-by":"publisher","first-page":"e0233947","DOI":"10.1371\/journal.pone.0233947","volume":"15","author":"I Ragan","year":"2020","unstructured":"Ragan I, Hartson L, Pidcoke H, Bowen R, Goodind R. Pathogen reduction of SARS-CoV-2 virus in plasma and blood using riboflavin and UV light. PLoS ONE. 2020;15(5):e0233947.","journal-title":"PLoS ONE"},{"key":"400_CR41","unstructured":"Gharbharan C, Jordans C Geurts van Kessel C, et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv 2020.07.01.20139857."},{"issue":"10289","key":"400_CR42","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049\u201359.","journal-title":"Lancet"},{"issue":"1","key":"400_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13613-021-00867-9","volume":"11","author":"S Hatzl","year":"2021","unstructured":"Hatzl S, Posch F, Sareban N, et al. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. Ann Intensive Care. 2021;11(1):73.","journal-title":"Ann Intensive Care"},{"key":"400_CR44","unstructured":"Wang L, Zhou T, Zhang Y, et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021;373(6556):eabh1766."},{"key":"400_CR45","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomised trial of convalescent plasma in Covid-19 severe pneumonia. New Eng J Med. 2021;384:619\u201324.","journal-title":"New Eng J Med"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-021-00400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-021-00400-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-021-00400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:13:22Z","timestamp":1744715602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-021-00400-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s40290-021-00400-0","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"type":"print","value":"1178-2595"},{"type":"electronic","value":"1179-1993"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"8 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neither Dr Seifner nor Dr Fox received any funding for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs. Seifner and Fox have no conflicts of interest that are relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This article derives from a dissertation presented by Dr. Seifner in partial fulfilment of requirements for an M.Sc. degree at King\u2019s College London, and Dr. Tony Lockett is kindly acknowledged. Both authors meet the ICMJE criteria for authorship. Both authors drafted and critically revised the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"This article required no acquisition of human data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}